Breaking News Instant updates and real-time market news.

MNTA

Momenta

$14.95

-0.3 (-1.97%)

, BMY

Bristol-Myers

$58.70

0.005 (0.01%)

14:22
12/22/16
12/22
14:22
12/22/16
14:22

Momenta loses patent challenge against Bristol-Myers' Orencia, Bloomberg reports

MNTA

Momenta

$14.95

-0.3 (-1.97%)

BMY

Bristol-Myers

$58.70

0.005 (0.01%)

  • 19

    Jan

  • 26

    Jan

  • 21

    Feb

MNTA Momenta
$14.95

-0.3 (-1.97%)

10/11/16
LEHM
10/11/16
UPGRADE
Target $19
LEHM
Overweight
Momenta upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Douglas Tsao upgraded Momenta Pharmaceuticals to Overweight after attending the consolidated Copaxone 40mg trial. The analyst sees low risk of Momenta being blocked from the 40mg opportunity past 2018 and views the stock's risk/reward as "compelling" at current levels. Tsao believes there is a "good likelihood" that Sandoz, Momenta's partner, launches Copaxone 40mg at-risk as soon as February 2017 upon FDA approval when the 30-month stay expires. The analyst raised his price target for Momenta shares to $19 from $13.
11/22/16
AGIS
11/22/16
INITIATION
Target $15
AGIS
Hold
Momenta initiated with a Hold at Aegis
Aegis analyst Difei Yang iniatied Momenta with a Hold and a $15 price target.
11/29/16
MAXM
11/29/16
NO CHANGE
Target $6
MAXM
Sell
Momenta launch of Humira biosimilar could be delayed, says Maxim
Maxim analyst Jason McCarthy continues to believe that Momenta Pharmaceuticals' launch of M923, a biosimilar of Humira, could be delayed after the company said a Phase III study met its endpoint. The results are not a surprise as the question is not efficacy, it is legal, McCarthy tells investors in a research note. He believes Momenta put too much emphasis on "science/technology" when it comes to biosimilars and not enough on intellectual property. McCarthy keeps a Sell rating on Momenta shares with a $6 price target. The stock is up 30c to $14.20 in afternoon trading.
11/29/16
MAXM
11/29/16
NO CHANGE
Target $6
MAXM
Sell
Question on Momenta's biosimilar Humira not efficacy, but legality, says Maxim
Maxim analyst Jason McCarthy noted that Momenta (MNTA) announced that M923, its biosimilar version of Humira, met the primary endpoint in a trial of its efficacy, but added that the question about the product "is not efficacy, it is legal." If M923 is approved, a fight over IP with AbbVie (ABBV) could delay the commercial launch to 2022 or later, said McCarthy, who keeps a Sell rating on Momenta shares.
BMY Bristol-Myers
$58.70

0.005 (0.01%)

12/01/16
COWN
12/01/16
NO CHANGE
Target $85
COWN
Outperform
Bristol-Myers price target lowered to $85 from $100 at Cowen
Cowen analyst Steve Scala lowered his price target on Bristol-Myers to $85 from $100 due to the increased competition in the PD-1/PD-L1 area. However, following a meeting with management the analyst came away with stronger conviction in both the company's strategy and pipeline. Scala maintained his Buy rating on Bristol-Myers shares.
12/19/16
JEFF
12/19/16
UPGRADE
Target $69
JEFF
Buy
Bristol-Myers upgraded to Buy from Hold at Jefferies
Jefferies analyst Jeffrey Holford upgraded Bristol-Myers Squibb (BMY) to Buy on expectations the company will share with AstraZeneca (AZN) the cytotoxic T-lymphocyte-associated antigen-4 combo opportunity in non-small cell lung cancer. Holford views Bristol shares as attractive valued and upped his price target for the name to $69 from $60.
12/19/16
JEFF
12/19/16
DOWNGRADE
Target $48
JEFF
Underperform
Merck downgraded to Underperform from Hold at Jefferies
Jefferies analyst Jeffrey Holford downgraded Merck (MRK) to Underperform, his firm's sell-rating equivalent. The analyst sees Pharmaceutical sector fundamentals weakening in 2017 amid political overhangs and an adverse macro environment. Potential dual eligible rebate reform is the most significant risk, Holford tells investors in a research note. Specific to Merck, the analyst expects further pressure on Keytruda in 2018, driven by share losses in non-small cell lung cancer to Bristol-Myers Squibb (BMY), AstraZeneca (AZN) and Roche (RHHBY). Merck screens poorly on many valuation metrics, Holford contends. He lowered his price target for the shares to $48 from $59. The stock closed Friday up 7c to $62.44. The analyst this morning also upgraded both Bristol-Myers Squibb (BMY) and Bayer (BAYRY) to Buy from Hold. His top picks in Pharmaceuticals are AbbVie (ABBV) and Eli Lilly (LLY) for the U.S. and AstraZeneca and Novartis (NVS) in Europe.
12/19/16
12/19/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Bristol-Myers (BMY) and Bayer (BAYRY) were upgraded to Buy from Hold at Jefferies. 2. Costco (COST) upgraded to Buy from Neutral at Citi with analyst Kate McShane saying she sees a "clear path" to accelerating same-store-sales growth in fiscal 2017 as gasoline price deflation headwinds abate and benefits arise from the new co-branded credit card. 3. United Technologies (UTX) upgraded to Outperform from Neutral at Credit Suisse with analyst Julian Mitchell saying he believes consensus estimates are poised to move higher after years of heavy investment spending drive an earnings recovery. 4. ASML (ASML) upgraded to Buy from Neutral at BofA/Merrill with analyst Kai Korschelt saying a recent expert's call indicates progress with Extreme Ultraviolet/EUV lightsource optics & ecosystem and sees improving volume visibility from 2018 forward. 5. Gulfport Energy (GPOR) upgraded to Buy from Neutral at Guggenheim and to Overweight from Equal Weight at Stephens. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

IBB

iShares Nasdaq Biotechnology Index

$312.52

1.81 (0.58%)

06:19
11/24/17
11/24
06:19
11/24/17
06:19
Technical Analysis
iShares Nasdaq Biotechnology Index: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LABD

Daily S&P Biotech Bear 3x Shares

$5.34

-0.09 (-1.66%)

06:19
11/24/17
11/24
06:19
11/24/17
06:19
Technical Analysis
Daily S&P Biotech Bear 3x Shares: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAYRY

Bayer

$32.05

-0.15 (-0.47%)

, NKTR

Nektar

$49.75

-0.23 (-0.46%)

06:19
11/24/17
11/24
06:19
11/24/17
06:19
Hot Stocks
Bayer announces INHALE Phase III clinical study did not meet primary endpoint »

Bayer (BAYRY) announced…

BAYRY

Bayer

$32.05

-0.15 (-0.47%)

NKTR

Nektar

$49.75

-0.23 (-0.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EWH

MSCI Hong Kong Index

$26.02

0.02 (0.08%)

06:19
11/24/17
11/24
06:19
11/24/17
06:19
Technical Analysis
MSCI Hong Kong Index: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EWG

iShares MSCI Germany

$32.82

-0.22 (-0.67%)

06:18
11/24/17
11/24
06:18
11/24/17
06:18
Technical Analysis
iShares MSCI Germany: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NCMGY

Newcrest Mining

$18.13

0.2 (1.12%)

06:18
11/24/17
11/24
06:18
11/24/17
06:18
Downgrade
Newcrest Mining rating change  »

Newcrest Mining…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IJR

iShares Core S&P Small Cap ETF

$76.06

-0.16 (-0.21%)

06:16
11/24/17
11/24
06:16
11/24/17
06:16
Technical Analysis
iShares Core S&P Small Cap ETF: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EEM

MSCI Emerging Markets Index

$47.81

0.12 (0.25%)

06:16
11/24/17
11/24
06:16
11/24/17
06:16
Technical Analysis
MSCI Emerging Markets Index: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EWW

iShares MSCI Mexico

$51.43

0.4 (0.78%)

06:14
11/24/17
11/24
06:14
11/24/17
06:14
Technical Analysis
iShares MSCI Mexico: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CPYYY

Centrica

$8.66

0.18 (2.12%)

06:14
11/24/17
11/24
06:14
11/24/17
06:14
Upgrade
Centrica rating change  »

Centrica upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DISH

Dish

$50.43

0.39 (0.78%)

, CBS

CBS

$56.24

-0.5 (-0.88%)

06:14
11/24/17
11/24
06:14
11/24/17
06:14
Hot Stocks
Dish reaches multi-year carriage agreement with CBS, terms not disclosed »

DISH Network (DISH) has…

DISH

Dish

$50.43

0.39 (0.78%)

CBS

CBS

$56.24

-0.5 (-0.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UUP

PowerShares DB US Dollar Index Up

$24.24

-0.19 (-0.78%)

06:14
11/24/17
11/24
06:14
11/24/17
06:14
Technical Analysis
PowerShares DB US Dollar Index Up: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UDN

PowerShares DB US Dollar Index Down

$22.23

0.1881 (0.85%)

06:13
11/24/17
11/24
06:13
11/24/17
06:13
Technical Analysis
PowerShares DB US Dollar Index Down: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEVA

Teva

$13.48

0.15 (1.13%)

06:10
11/24/17
11/24
06:10
11/24/17
06:10
Periodicals
Teva to slash up to 25% of Israeli workforce, Bloomberg reports »

Teva intends to cut as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BASFY

BASF

$27.39

-0.13 (-0.47%)

04:55
11/24/17
11/24
04:55
11/24/17
04:55
Conference/Events
BASF management to meet with Evercore ISI »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Nov

04:55
11/24/17
11/24
04:55
11/24/17
04:55
General news
PMI Composite Flash Manufacturing â€' Level to be reported at 09:45 »

November PMI Composite…

RBS

RBS

$7.30

-0.04 (-0.54%)

04:55
11/24/17
11/24
04:55
11/24/17
04:55
Conference/Events
RBS management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Nov

04:55
11/24/17
11/24
04:55
11/24/17
04:55
General news
Breaking General news story  »

Week of 11/22 Fed Balance…

04:55
11/24/17
11/24
04:55
11/24/17
04:55
General news
Breaking General news story  »

Week of 11/24…

04:55
11/24/17
11/24
04:55
11/24/17
04:55
General news
Breaking General news story  »

Week of 11/13 Money…

04:55
11/24/17
11/24
04:55
11/24/17
04:55
Conference/Events
RBC Capital to hold field trip »

European Utilities Field…

04:55
11/24/17
11/24
04:55
11/24/17
04:55
General news
PMI Composite Flash â€' Level to be reported at 09:45 »

November PMI Composite…

02:45
11/24/17
11/24
02:45
11/24/17
02:45
General news
FX Update: The dollar has managed to find a footing »

FX Update: The dollar…

10:30
11/23/17
11/23
10:30
11/23/17
10:30
General news
FX Action: EUR-USD, USD-JPY and other major pairings are in sideways mode »

FX Action: EUR-USD,…

DE

Deere

$145.25

6.02 (4.32%)

09:53
11/23/17
11/23
09:53
11/23/17
09:53
Upgrade
Deutsche Bank gets off sidelines, upgrades Deere shares to Buy »

Deutsche Bank analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.